Abstract
We report two cases of advanced pancreatic cancer treated with CPT-11 and CDDP as third-line chemotherapy. CPT-11 was administered as an intravenous injection at a dose of 60 mg/m2, and CDDP was administered at a dose of 30 mg/m2 biweekly. The patients showed no adverse events greater than grade 2 toxicity, and these adverse events were tolerated. The patients showed partial response and stable disease. These results suggested that this treatment schedule was safe and effective for progressive pancreatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 847-849 |
| Number of pages | 3 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 39 |
| Issue number | 5 |
| Publication status | Published - May 2012 |
| Externally published | Yes |
Keywords
- CPT-11 and CDDP chemotherapy
- Pancreatic cancer
ASJC Scopus subject areas
- Medicine(all)
